"Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls
- PMID: 33340582
- DOI: 10.1016/j.jhep.2020.11.004
"Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls
Conflict of interest statement
Conflict of interest Christophe Moreno was paid as consultant for Abbvie, Astellas, Bayer, Gilead Sciences, Norgine, Novartis; Nick Sheron: Clinical adviser to Public Health England. Other advisory work: Alcohol Health Alliance UK, UK Department of Health, Home Office, British Liver Trust, European Public Health Alliance, European Society for the Study of Liver Disease, British Society for the Study of Liver Disease. Consultancy work and travelling expenses from pharmaceutical companies: Norgine and Kyowa Kirin Limited, Gilead; Dina Tiniakos: nothing to declare; Carolin Lackner was paid as consultant for Allergan, Verily, Histoindex, Dr. Falk Pharma GmbH, Galmed Research and Development Ltd; Philippe Mathurin was paid as consultant for Sanofi, Gilead Sciences, Novo Nordisk, Intercept, Generon. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
MAFLD: A holistic view to redefining fatty liver disease.J Hepatol. 2021 Apr;74(4):983-985. doi: 10.1016/j.jhep.2020.12.027. Epub 2021 Jan 13. J Hepatol. 2021. PMID: 33453330 No abstract available.
Comment on
-
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278004 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
